Supplier News--Eisai last month closed the deal on acquiring the epilepsy treatment Zonegran (zonisamide) from Elan Pharma.
As part of the agreement, Eisai acquired exclusive North American and European manufacturing, development and marketing rights to Zonegran.
Financial terms were not disclosed. Zonegran generated $80.7 million in U.S. sales in 2003.
The acquisition represents Eisai's third agreement in the epilepsy arena. In February, Eisai in-licensed rufinamide from Novartis Pharma, and in 2002, Eisai acquired the exclusive rights to promote Pfizer's Cerebyx (fosphenytoin sodium injection).
Another anticipated addition to Eisai's neurology product line results from a May 2003 agreement with Teva for the co-development of rasagiline for Alzheimer's disease and co-promotion in the United States for Parkinson's disease, if the Food and Drug Administration approves the drug.
COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group